A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-10. Anything still debated is marked as such rather than presented as settled.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
1993/1887) Occupational Pension Schemes (Public Service Pension Schemes) (Amendment) Regulations 1993 (S.I. 1993/1888) Magistrates' Courts Fees (Amendment) Order 1993 (S.I. 1993/1889) Medicines (Products Other Than Veterinary Dmgs) (Prescription Only) Amendment Order 1993 (S.I. 1993/1890) Colleges of Further Education (Changes of Names) (Scotland) Order 1993 (S.I. 1993/1891) Education (Access Funds) (Scotland) Amendment Regulations 1993 (S.I. 1993/1892) Offshore Installations (Safety Zones)(No. 3) Order 1993 (S.I. 1993/1893) Assisted Areas (Amendment) Order 1993 (S.I. 1993/1894) Legal Aid in Criminal and Care Proceedings (General) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/1895) Neath—Abergavenny Trunk Road (A465) (Improvement from Aberdulais to Glynneath, Aberdulais Slip Roads) Order 1993 (S.I. 1993/1896) Management and Administration of Safety and Health at Mines Regulations 1993 (S.I. 1993/1897) Poultry Breeding Flocks and Hatcheries Order 1993 (S.I. 1993/1898) Meat and Livestock Commission Levy (Variation) Scheme (Confirmation) Order 1993 (S.I. 1993/1899)
=== Chemical flocculant === Potassium alum has been used since remote antiquity for purification of turbid liquids. It is still widely used in the purification of water for drinking and industrial processes water, treatment of effluents and post-storm treatment of lakes to precipitate contaminants. Between 30 and 40 ppm of alum for household wastewater, often more for industrial wastewater, is added to the water so that the negatively charged colloidal particles clump together into "flocs", which then float to the top of the liquid, settle to the bottom of the liquid, or can be more easily filtered from the liquid, prior to further filtration and disinfection of the water. Like other similar salts, it works by neutralizing the electrical double layer surrounding very fine suspended particles, allowing them to join into flocs. The same principle is exploited when using alum to increase the viscosity of a ceramic glaze suspension; this makes the glaze more readily adherent and slows its rate of sedimentation.
=== RNA genomes === Like DNA, RNA can carry genetic information. RNA viruses have genomes composed of RNA that encodes a number of proteins. The viral genome is replicated by some of those proteins, while other proteins protect the genome as the virus particle moves to a new host cell. Viroids are another group of pathogens, but they consist only of RNA, do not encode any protein and are replicated by a host plant cell's polymerase.
Sources: en.wikipedia.org
Referral to an out-patient genetics clinic (pediatric, adult, or combined) or an in-hospital consultation, most often for diagnostic evaluation. Specialty genetics clinics focusing on management of inborn errors of metabolism, skeletal dysplasia, or lysosomal storage diseases. Referral for counseling in a prenatal genetics clinic to discuss risks to the pregnancy (advanced maternal age, teratogen exposure, family history of a genetic disease), test results (abnormal maternal serum screen, abnormal ultrasound), and/or options for prenatal diagnosis (typically non-invasive prenatal screening, diagnostic amniocentesis or chorionic villus sampling). Multidisciplinary specialty clinics that include a clinical geneticist or genetic counselor (cancer genetics, cardiovascular genetics, craniofacial or cleft lip/palate, hearing loss clinics, muscular dystrophy/neurodegenerative disorder clinics).
=== Template-dependent DNA ligation === Template-dependent DNA ligation is a fragment-based oligonucleotide assembly method in which shorter, chemically synthesized oligonucleotide segments are aligned on a complementary nucleic acid template then joined through enzymatic ligation. This approach has been developed by a research group at Institute Pasteur and works as an alternative approach in order to overcome the length limitations of traditional methods. In one study, short oligonucleotide fragments, or ‘shortmers’, are designed to complement a given template strand, with correct positioning and orientation. DNA ligases can then be used to catalyze the formation of phosphodiester bonds between adjacent shortmers and create a continuous oligonucleotide strand. The incorporation of a template strand improves method specificity by promoting accurate base-pairing as well as reducing concatenation errors that occur during stepwise synthesis. Template-dependent ligation also enables the incorporation of chemically modified nucleotides, which can be more difficult using traditional synthesis techniques. As the individual shortmers are synthesized and purified prior to the assembly of the strand, the method allows for a reduction in cumulative yield loss and cumulative error compared to stepwise synthesis of long strands. These benefits push the method forward as a possible modular approach to construct longer and more complex oligonucleotides. Despite these advantages, template-dependent DNA ligation still has multiple limitations.
== Structure == Elastic cartilage is histologically similar to hyaline cartilage but contains many yellow elastic fibers lying in a solid matrix. These fibers form bundles that appear dark under a microscope. The elastic fibers require special staining since when it is stained using haematoxylin and eosin (H&E) stain it appears the same as hyaline cartilage. Verhoeff van Geison stains are used (giving the elastic fibers a black color), but aldehyde fuchsin stains, Weigert's elastic stains, and orcein stains also work. These fibers give elastic cartilage great flexibility so that it is able to withstand repeated bending. Similarly to hyaline one or multiple chondrocytes lie between the spaces (or lacunae) in the fibres. The chondrocytes only make up 2% of the tissue's volume. Chondrocytes and the extracellular matrix are contained in an outerlayer named the perichondrium (which is a layer of dense irregular connective tissue that surrounds cartilage which is independent of the joint). It is found in the epiglottis (part of the larynx), and the pinnae (the external ear flaps of many mammals). Elastin fibers stain dark purple/black with Verhoeff's stain. The extracellular matrix contains elastin, fibrillin, glycoproteins, collagen types II, IX, X, and XI, and the proteoglycan aggrecan. the components within the extracellular matrix are produced by the chondroblasts located within the edges of the perichondrium. Elastic fibers within the extracellular matrix are made up of elastin proteins which co-polymerize with fibrillin forming fiber-like elastic chains.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.